Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ZFN modified T cell (SB-313)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sangamo Therap

Drug class:

Immunomodulator, Cytotoxic T lymphocyte stimulant

Related drugs:

mouse TYRP2 DNA (0)

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

coprelotamab (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

cytotoxic lymphocyte-based cancer vaccine (0)

GSK2130579A (0)

GSK2302025A (0)

HA-1 T TCR T Cell Immunotherapy (0)

SQZ-PBMC-HPV (0)

tabelecleucel (0)

mouse TYRP2 DNA (0)

›